Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
2 papers
Research so far says MDMA can help reduce strong anxiety symptoms in carefully run therapy studies. Most of the clinical work with MDMA has focused on post‑traumatic stress disorder (PTSD), where several trials show big improvements. There are fewer and smaller studies that test MDMA specifically for general worry or other anxiety disorders, so the evidence there is more limited. Scientists agree that the drug’s effects depend a lot on the therapy around it. Trials done in medical settings with careful screening, preparation, and follow-up report mostly favorable safety results. But studies are still small, not very diverse, and the exact brain reasons why MDMA helps are not settled. More and larger trials are needed before we know how well MDMA works for everyday anxiety or how safe it is outside tightly controlled research settings.
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
Researchers reviewed the fast-growing interest in psychedelic therapies. They found that even though hundreds of studies are under way, no psychedelic medicine is officially approved for any mental health condition yet. The review explains the kinds of drugs being tested, the conditions people hope to treat, and big challenges such…
